Search results
May 31, 2024 · Hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in non-human primate model. Get a real-time Sana Biotechnology, Inc. (SANA) stock price quote with breaking news, financials, statistics, charts and more.
4 days ago · Should You Buy or Sell Sana Biotechnology Stock? Get The Latest SANA Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat.
4 days ago · See the latest Sana Biotechnology Inc Ordinary Shares stock price (SANA:XNAS), related news, valuation, dividends and more to help you make your investing decisions.
May 31, 2024 · Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders.
5 days ago · (NASDAQ: SANA) Sana Biotechnology currently has 221,502,908 outstanding shares. With Sana Biotechnology stock trading at $7.81 per share, the total value of Sana Biotechnology stock (market capitalization) is $1.73B.
May 30, 2024 · A high-level overview of Sana Biotechnology, Inc. (SANA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
1 day ago · It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma.
